• SR-202: Mechanistic Precision and Translational Opportuni...

  2026-01-20

  SR-202, a selective PPARγ antagonist from APExBIO, is redefining research into insulin resistance, obesity, and immune-metabolic crosstalk. This thought-leadership article integrates new findings on macrophage polarization, experimental design strategies, and the unique advantages of SR-202 over conventional tools, offering translational researchers a roadmap to accelerate advances in metabolic disease and inflammatory disorder research.

• SGC-CBP30: Selective Bromodomain Inhibitor for Epigenetic...

  2026-01-19

  SGC-CBP30 empowers researchers to precisely dissect CREBBP/EP300-driven transcriptional programs, especially in the context of super-enhancer hijacking and TGF-β/SMAD3 signaling. Its high selectivity and robust cellular activity make it a cornerstone for advanced epigenetics and cancer biology workflows, with proven value in lung adenocarcinoma models.

407 records 28/28 page Previous First page 上5页 262728